Literature DB >> 25941161

Metabolic abnormalities of the heart in type II diabetes.

Nelson Amaral1, Darlington O Okonko2.   

Abstract

Type 2 diabetes mellitus escalates the risk of heart failure partly via its ability to induce a cardiomyopathic state that is independent of coronary artery disease and hypertension. Although the pathogenesis of diabetic cardiomyopathy has yet to be fully elucidated, aberrations in cardiac substrate metabolism and energetics are thought to be key drivers. These aberrations include excessive fatty acid utilisation and storage, suppressed glucose oxidation and impaired mitochondrial oxidative phosphorylation. An appreciation of how these abnormalities arise and synergise to promote adverse cardiac remodelling is critical to their effective amelioration. This review focuses on disturbances in myocardial fuel (fatty acids and glucose) flux and energetics in type 2 diabetes, how these disturbances relate to the development of diabetic cardiomyopathy and the potential therapeutic agents that could be used to correct them.
© The Author(s) 2015.

Entities:  

Keywords:  Metabolism; diabetes; energetics

Mesh:

Substances:

Year:  2015        PMID: 25941161     DOI: 10.1177/1479164115580936

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  15 in total

Review 1.  Pet Imaging and its Application in Cardiovascular Diseases.

Authors:  Zheng Li; Anisha A Gupte; Anjun Zhang; Dale J Hamilton
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Jan-Mar

Review 2.  Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus.

Authors:  Gül Bahtiyar; David Gutterman; Harold Lebovitz
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

3.  Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats.

Authors:  Alaaeldin Ahmed Hamza; Ebtehal Mohammad Fikry; Wedad Abdallah; Amr Amin
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

Review 4.  Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective.

Authors:  Jinfan Tian; Yingke Zhao; Yanfei Liu; Yue Liu; Keji Chen; Shuzheng Lyu
Journal:  Oxid Med Cell Longev       Date:  2017-10-24       Impact factor: 6.543

5.  The Altered Signaling on EFS-Induced Colon Contractility in Diabetic Rats.

Authors:  Wynn Thein; Wah Wah Po; Dong Min Kim; Uy Dong Sohn
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

6.  The Inhibitory Mechanism on Acetylcholine-Induced Contraction of Bladder Smooth Muscle in the Streptozotocin-Induced Diabetic Rat.

Authors:  Jong Soo Han; Su Jin Kim; Yoonjin Nam; Hak Yeong Lee; Geon Min Kim; Dong Min Kim; Uy Dong Sohn
Journal:  Biomol Ther (Seoul)       Date:  2019-01-01       Impact factor: 4.634

Review 7.  Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.

Authors:  Aaron Kithcart; Calum A MacRae
Journal:  JACC Basic Transl Sci       Date:  2017-02-27

8.  The change of signaling pathway on the electrical stimulated contraction in streptozotocin-induced bladder dysfunction of rats.

Authors:  Jong Soo Han; Young Sil Min; Gil Hyung Kim; Sang-Hyun Chae; Yoonjin Nam; Jaehwi Lee; Seok-Yong Lee; Uy Dong Sohn
Journal:  Korean J Physiol Pharmacol       Date:  2018-08-27       Impact factor: 2.016

Review 9.  Diabetic Cardiomyopathy Modelling Using Induced Pluripotent Stem Cell Derived Cardiomyocytes: Recent Advances and Emerging Models.

Authors:  Cecilia Granéli; Ryan Hicks; Gabriella Brolén; Jane Synnergren; Peter Sartipy
Journal:  Stem Cell Rev Rep       Date:  2019-02       Impact factor: 5.739

10.  Loss of protein kinase D activity demonstrates redundancy in cardiac glucose metabolism and preserves cardiac function in obesity.

Authors:  Kirstie A De Jong; Liam G Hall; Mark C Renton; Timothy Connor; Sheree D Martin; Greg M Kowalski; Christopher S Shaw; Clinton R Bruce; Kirsten F Howlett; Sean L McGee
Journal:  Mol Metab       Date:  2020-10-21       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.